%0 Journal Article
%T Switching to secukinumab in difficult
%A Aastha Gupta
%A Kabir Sardana
%A Ram K Gautam
%J Tropical Doctor
%@ 1758-1133
%D 2019
%R 10.1177/0049475519838400
%X Several biological agents have been approved for the treatment of recalcitrant psoriasis. However, there is a lack of a consensus algorithm guiding the drug selection for patients who have failed conventional drugs. In cases not improving with cyclosporine, direct switching to a biological therapy usually leads to a disease flare owing to increased production of interleukin (IL)-17A. Thus, secukinumab, a rapidly acting anti-IL-17A drug, may be ideal in such situations
%K Secukinumab
%K recalcitrant psoriasis
%K cyclosporine
%K interleukin-17
%K tuberculosis-endemic country
%U https://journals.sagepub.com/doi/full/10.1177/0049475519838400